Jorge Abreu is not a doctor. This is an educational research summary, not a prescription or a personal dosing plan. Study results do not establish that a supplier product is safe or effective for people. Consult a licensed clinician about medical decisions.
01Melanotan 1's approved relative
Melanotan 1 is a linear analog of alpha-melanocyte-stimulating hormone. The same molecule, afamelanotide, is approved in some jurisdictions as a subcutaneous implant for erythropoietic protoporphyria, a rare condition causing severe light sensitivity, not for cosmetic tanning.
02PT-141's FDA approval
Bremelanotide, referred to by suppliers as PT-141, is a melanocortin receptor agonist FDA-approved under the brand Vyleesi as an on-demand subcutaneous injection for acquired generalized hypoactive sexual desire disorder in premenopausal women, a specific diagnosis with a defined clinical dose.
03The gap between the approved use and the marketing
Neither approval covers the way these compounds are typically marketed by research suppliers: Melanotan 1 as a general tanning product, PT-141 as a general libido enhancer for any user. The approved formulations, doses and patient populations are narrower than the supplier marketing suggests.
Bottom line: Both compounds are linked to real FDA or international approvals, for specific conditions and specific dosing under medical supervision, not for the general cosmetic or lifestyle use they are usually sold for.
Read the full guides
Human studies↗
Pigmentation and sexual health
Afamelanotide, the approved drug, is manufactured and delivered as a 16mg subcutaneous implant placed by a clinician for a specific rare disease indication. Reign Peptide's Melanotan 1 is a lyophilized research-chemical powder of the same or closely related linear peptide sequence, intended by the seller for laboratory reconstitution, not the approved implant device, route, or indication; the two are not interchangeable products.
Read the research →
Human studies↗
Pigmentation and sexual health
Bremelanotide as approved (Vyleesi) is dispensed as a single-use, prefilled autoinjector for a specific FDA-cleared indication in a defined patient population. Reign Peptide sells the same peptide sequence as a lyophilized powder vial or nasal spray for research use, not as the approved autoinjector device, and no bioequivalence between these research formats and Vyleesi was identified in the sources reviewed.
Read the research →
Reign Peptide · Business disclosure
Research product listings
Jorge Abreu is involved in Reign Peptide. Links to Reign are a business connection, not an independent endorsement. Reign lists these products for laboratory research, not human consumption.
Use the listing to check the labeled identity, amount and available batch documentation. A purity result alone does not verify sterility, clinical suitability or equivalence to a medicine used in a trial.
Names and sizes are product labels, not dosing recommendations. Confirm current details with the seller.